Anoro Ellipta (Umeclidinium Brm/Vilanterol Tr) Patent Expiration, LOE Window & CMS Spending

Anoro Ellipta (Umeclidinium Brm/Vilanterol Tr) by GSK: FDA Orange Book core substance LOE 2027-12-18 (last listed 2030-11-29), 0 AB generics, $970.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN203975 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-12-18
Last Listed Patent or Exclusivity Date2030-11-29
Orange Book Patents (*PED Extensions)6 patents (1 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$970.9M
2024 Medicare Part D Spend$819.3M
2024 Medicaid Spend$151.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.